A three-judge panel has reversed a $7 million judgment against the maker of the acne drug Accutane.
The 1st District Court of Appeal panel ruled in favor of Hoffman-La Roche Inc. and against a Pensacola man who had most of his colon removed due to Crohn’s disease linked to Accutane.
The unanimous opinion said the patient, Adam Mason, failed to prove an allegedly deficient warning label was the proximate cause of his ailment.
Mason had argued warning that Accutane was “temporally associated” with inflammatory bowel disease was too weak.
But his dermatologist testified he would have prescribed the drug even if the warning had been stronger.
Copyright 2026 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Was this article valuable?
Here are more articles you may enjoy.
These Five Technologies Increase The Risk of Cyber Claims
Portugal Rolls Out $2.9 Billion Aid as Deadly Flooding Spreads
Why 2026 Is The Tipping Point for The Evolving Role of AI in Law and Claims
Elon Musk Alone Can’t Explain Tesla’s Owner Exodus